1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Molecular Targeting Technologies, Inc. - Product Pipeline Review - 2015

Molecular Targeting Technologies, Inc. - Product Pipeline Review - 2015

  • August 2015
  • -
  • Global Markets Direct
  • -
  • 24 pages

Molecular Targeting Technologies, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Molecular Targeting Technologies, Inc. - Product Pipeline Review - 2015’, provides an overview of the Molecular Targeting Technologies, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Molecular Targeting Technologies, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Molecular Targeting Technologies, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Molecular Targeting Technologies, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Molecular Targeting Technologies, Inc.’s pipeline products

Reasons to buy

- Evaluate Molecular Targeting Technologies, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Molecular Targeting Technologies, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Molecular Targeting Technologies, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Molecular Targeting Technologies, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Molecular Targeting Technologies, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Molecular Targeting Technologies, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Molecular Targeting Technologies, Inc. - Product Pipeline Review - 2015
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Molecular Targeting Technologies, Inc. Snapshot 4
Molecular Targeting Technologies, Inc. Overview 4
Key Information 4
Key Facts 4
Molecular Targeting Technologies, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Molecular Targeting Technologies, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Molecular Targeting Technologies, Inc. - Pipeline Products Glance 9
Molecular Targeting Technologies, Inc. - Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Molecular Targeting Technologies, Inc. - Early Stage Pipeline Products 10
Preclinical Products/Combination Treatment Modalities 10
Molecular Targeting Technologies, Inc. - Drug Profiles 11
SO-57 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
SOJB 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
botulinum vaccine 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
rabies vaccine 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
SMDC-T1 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
Molecular Targeting Technologies, Inc. - Pipeline Analysis 17
Molecular Targeting Technologies, Inc. - Pipeline Products by Target 17
Molecular Targeting Technologies, Inc. - Pipeline Products by Route of Administration 18
Molecular Targeting Technologies, Inc. - Pipeline Products by Molecule Type 19
Molecular Targeting Technologies, Inc. - Pipeline Products by Mechanism of Action 20
Molecular Targeting Technologies, Inc. - Recent Pipeline Updates 21
Molecular Targeting Technologies, Inc. - Locations And Subsidiaries 22
Head Office 22
Appendix 23
Methodology 23
Coverage 23
Secondary Research 23
Primary Research 23
Expert Panel Validation 23
Contact Us 23
Disclaimer 24

List of Tables
Molecular Targeting Technologies, Inc., Key Information 4
Molecular Targeting Technologies, Inc., Key Facts 4
Molecular Targeting Technologies, Inc. - Pipeline by Indication, 2015 6
Molecular Targeting Technologies, Inc. - Pipeline by Stage of Development, 2015 7
Molecular Targeting Technologies, Inc. - Monotherapy Products in Pipeline, 2015 8
Molecular Targeting Technologies, Inc. - Phase II, 2015 9
Molecular Targeting Technologies, Inc. - Preclinical, 2015 10
Molecular Targeting Technologies, Inc. - Pipeline by Target, 2015 17
Molecular Targeting Technologies, Inc. - Pipeline by Route of Administration, 2015 18
Molecular Targeting Technologies, Inc. - Pipeline by Molecule Type, 2015 19
Molecular Targeting Technologies, Inc. - Pipeline Products by Mechanism of Action, 2015 20
Molecular Targeting Technologies, Inc. - Recent Pipeline Updates, 2015 21

List of Figures
Molecular Targeting Technologies, Inc. - Pipeline by Top 10 Indication, 2015 6
Molecular Targeting Technologies, Inc. - Pipeline by Stage of Development, 2015 7
Molecular Targeting Technologies, Inc. - Monotherapy Products in Pipeline, 2015 8
Molecular Targeting Technologies, Inc. - Pipeline by Top 10 Target, 2015 17
Molecular Targeting Technologies, Inc. - Pipeline by Top 10 Molecule Type, 2015 19

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H2 2016

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Human Cytomegalovirus Envelope Glycoprotein B (gB) - Pipeline Review, H2 2016’, provides ...

Mycobacterium tuberculosis Protein Ag85A - Pipeline Review, H2 2016

Mycobacterium tuberculosis Protein Ag85A - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Mycobacterium tuberculosis Protein Ag85A - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Mycobacterium tuberculosis Protein Ag85A - Pipeline Review, H2 2016’, provides in depth analysis ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.